Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Twist Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Twist Bioscience's regulatory disclosures and financial reporting.
Twist Bioscience Corporation disclosed that investment manager Artisan Partners and related entities filed an amended Schedule 13G reporting a sizable passive stake. The group reports beneficial ownership of 5,830,205 shares of Twist common stock, or 9.5% of the class, based on 61,273,653 shares outstanding as of 12/26/2025.
Artisan entities report no sole voting or dispositive power. They share voting power over 4,959,392 shares and share dispositive power over 5,830,205 shares, held on behalf of discretionary clients of Artisan Partners Limited Partnership. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Twist Bioscience.
Twist Bioscience Corp reported a significant shareholder update as of December 31, 2025. ARK Investment Management LLC and its founder Catherine D. Wood together beneficially own 7,559,495 shares of Twist common stock, representing 12.36% of the outstanding class.
ARK holds sole voting power over 7,091,113 shares and sole dispositive power over all 7,559,495 shares. Catherine Wood has shared voting power over 7,227,245 shares and shared dispositive power over 7,559,495 shares, reflecting her control role at ARK.
The filing states that these securities were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing control of Twist Bioscience, and not in connection with any control-related transaction. ARK also notes that its client ARK Innovation ETF has an interest in more than 5% of the reported securities.
Twist Bioscience reported quarterly revenue of $103.7 million for the three months ended December 31, 2025, up 16.9% from $88.7 million a year earlier. Growth came from both DNA synthesis and protein solutions and NGS applications, with particularly strong demand from therapeutics and global supply partners.
Gross margin improved to 52.0% from 48.3% as higher volume and process improvements offset cost increases. The company still recorded a net loss of $30.5 million, slightly better than the $31.6 million loss last year, and used $24.8 million in operating cash.
Cash, cash equivalents and short-term investments totaled $197.9 million, and management believes this balance is sufficient to fund operations for at least one year. Operating expenses shifted, with lower research and development spending and higher selling, general and administrative costs to support commercial scaling.
Twist Bioscience Corporation filed a current report to note that it issued a press release announcing its financial results for the quarter ended December 31, 2025. The press release, titled “Twist Bioscience Reports Fiscal First Quarter 2026 Financial Results”, is furnished as Exhibit 99.1.
The company states that the information in this report, including Exhibit 99.1, is being furnished rather than filed under the Securities Exchange Act of 1934 and is not automatically incorporated by reference into Securities Act registration statements unless specifically referenced.
Twist Bioscience Corp's President and COO, Patrick John Finn, reported a small mandatory share sale related to equity compensation. On 01/23/2026, he sold 2,390 shares of common stock at $44.908 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units under the company's equity incentive plans and are described as non-discretionary trades. Following this transaction, he beneficially owned 310,493 shares of Twist Bioscience common stock directly.
An affiliate of TWST has filed a Rule 144 notice to sell 2,390 shares of common stock, with an aggregate market value of 107,329.41, through Fidelity Brokerage Services on NASDAQ around 01/23/2026.
These shares were acquired on 01/22/2026 via restricted stock vesting from the issuer as compensation. The filing also shows that Patrick Finn has sold multiple blocks of common stock over the past three months, including 23,279 shares on 01/13/2026 for gross proceeds of 931,160.00.
Twist Bioscience Corp’s Chief Financial Officer, Adam Laponis, reported a planned sale of company stock. On 01/13/2026, he sold 3,000 shares of Twist Bioscience common stock at a price of $40 per share. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan that he adopted on May 8, 2025, which is designed to allow insiders to sell shares according to a preset schedule. After this sale, Laponis directly beneficially owned 137,031 shares of Twist Bioscience common stock.
Twist Bioscience Corp President and COO Patrick John Finn reported an option exercise and share sale in the company’s stock. On January 13, 2026, he exercised a stock option for 3,279 shares of common stock at an exercise price of $8.82 per share and acquired those shares directly.
On the same date, he sold 23,279 shares of Twist Bioscience common stock at a price of $40 per share in an open-market transaction. After these transactions, Finn directly owned 312,883 shares of common stock. The filing notes that these transactions were carried out under a previously adopted Rule 10b5-1 trading plan put in place on May 13, 2025.
Twist Bioscience Corp's Chief Financial Officer, Adam Laponis, reported an automatic sale of common stock to cover taxes related to equity compensation. On January 9, 2026, he sold 2,738 shares of common stock at a price of $35.261 per share. According to the disclosure, these shares were sold to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units under the company's equity incentive plans and were executed as mandatory "sell to cover" transactions rather than discretionary trades. After this sale, Laponis directly beneficially owned 140,031 shares of Twist Bioscience common stock.
An affiliate of TWST has filed a Form 144 notice for a proposed sale of 23,279 shares of common stock through Fidelity Brokerage Services LLC, to be sold on NASDAQ around 01/13/2026. The filing lists an aggregate market value of $931,160.00 and notes that 61,148,026 shares of this class were outstanding.
The shares to be sold were acquired mainly through restricted stock vesting, an employee stock purchase plan, and an option granted on 09/29/2017, with acquisition and payment dates between 02/18/2022 and 02/20/2025. The notice also reports that Patrick Finn sold additional common shares over the prior three months on dates including 10/23/2025 and 10/30/2025, with individual transactions such as 2,240 shares for $69,159.78 and 17,606 shares for $553,608.35.